{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T09:21:10Z","timestamp":1787908870599,"version":"build-2784847793"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    Diabetic retinopathy (DR) is a leading cause of vision loss and a common microvascular complication of diabetes mellitus. Although diagnosis and management are typically guided by retinal findings, systemic metabolic factors\u2014including glycemic control, diabetes duration, blood pressure, renal function, lipid status, and overall complication burden\u2014play a central role in disease development and progression. Clinical decision-making often remains fragmented across endocrinology, primary care, and ophthalmology, contributing to variability in screening, referral, treatment selection, and patient education. This review proposes an integrated framework that applies endocrinology as a lens through which to better understand and manage diabetic retinopathy. The approach begins with a classification of systemic diabetes and metabolic disorders, then aligns these metabolically defined patient profiles with retinal diagnosis, monitoring, and stage-appropriate treatment strategies. Evidence is drawn from landmark endocrinology studies defining epidemiologic cohorts, diagnostic validation studies, and major randomized clinical trials as the basis for best practices in ophthalmological care. The goal is not only to synthesize evidence for clinicians, but also to support development of a concise patient-facing educational roadmap, presented as\n                    <jats:xref>supplementary material<\/jats:xref>\n                    , that summarizes disease progression, screening, treatment options, and anticipated next steps for patients. By integrating longitudinal endocrinology data with findings in ophthalmology, this framework may provide a strong rationale for interdisciplinary care, improve treatment outcomes, and promote more effective engagement of patients and their ophthalmologists in prevention and treatment of diabetic retinopathy.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1904880","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:58:14Z","timestamp":1787907494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Endocrinology concepts for diabetic retinopathy care: bridging systemic metabolic control with retinal disease management and patient education"],"prefix":"10.3389","volume":"13","author":[{"given":"Sidney","family":"Jones","sequence":"first","affiliation":[{"name":"Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri-Kansas City","place":["Kansas City, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Koulen","sequence":"additional","affiliation":[{"name":"Vision Research Center, Department of Ophthalmology, School of Medicine, University of Missouri-Kansas City","place":["Kansas City, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc26-S002","article-title":"2. Diagnosis and classification of diabetes: standards of care in diabetes-2026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"B2","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.2337\/dc26-S003","article-title":"3. Prevention or delay of diabetes and associated comorbidities: standards of care in diabetes-2026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"B3","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/S2213-8587(15)00291-0","article-title":"Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the diabetes prevention program outcomes study","volume":"3","author":"Nathan","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0161-6420(98)91020-X","article-title":"The Wisconsin epidemiologic study of diabetic retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes","volume":"105","author":"Klein","year":"1998","journal-title":"Ophthalmology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"Chew","year":"2010","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","article-title":"Diabetes complications severity index (DCSI)-update and ICD-10 translation","volume":"31","author":"Glasheen","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S2213-8587(18)30051-2","article-title":"Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables","volume":"6","author":"Ahlqvist","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e93751","DOI":"10.1172\/jci.insight.93751","article-title":"Diabetic retinopathy: current understanding, mechanisms, and treatment strategies","volume":"2","author":"Duh","year":"2017","journal-title":"JCI Insight"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41746-018-0040-6","article-title":"Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices","volume":"1","author":"Abramoff","year":"2018","journal-title":"NPJ Digit Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e2134254","DOI":"10.1001\/jamanetworkopen.2021.34254","article-title":"Pivotal evaluation of an artificial intelligence system for autonomous detection of referrable and vision-threatening diabetic retinopathy","volume":"4","author":"Ipp","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B13","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","article-title":"Grading diabetic retinopathy from stereoscopic color fundus photographs\u2014an extension of the modified airlie house classification. ETDRS report number 10","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1016\/j.ophtha.2015.01.008","article-title":"Peripheral lesions identified by mydriatic ultrawide field imaging predict increased risk of diabetic retinopathy progression over 4 years","volume":"122","author":"Silva","year":"2015","journal-title":"Ophthalmology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.ophtha.2006.10.055","article-title":"Reproducibility of macular thickness and volume using zeiss optical coherence tomography in patients with diabetic macular edema","volume":"114","author":"Krzystolik","year":"2007","journal-title":"Ophthalmology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1001\/jamaophthalmol.2021.2809","article-title":"Evaluation of intravitreal aflibercept for the treatment of severe nonproliferative diabetic retinopathy: results from the PANORAMA randomized clinical trial","volume":"139","author":"Brown","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jama.2022.25029","article-title":"Four-Year visual outcomes in the protocol W randomized trial of intravitreous aflibercept for prevention of vision-threatening complications of diabetic retinopathy","volume":"329","author":"Maturi","year":"2023","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","article-title":"Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies","volume":"123","author":"Heier","year":"2016","journal-title":"Ophthalmology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1001\/jama.2019.5790","article-title":"Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial","volume":"321","author":"Baker","year":"2019","journal-title":"JAMA"},{"key":"B21","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"YOSEMITE And RHINE investigators. Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.ophtha.2025.10.028","article-title":"Intravitreal aflibercept 8\u2005mg for diabetic macular edema: 96-week results from the PHOTON trial","volume":"133","author":"Do","year":"2025","journal-title":"Ophthalmology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0161-6420(81)34978-1","article-title":"Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of diabetic retinopathy study findings, DRS report number 8","volume":"88","year":"1981","journal-title":"Ophthalmology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","article-title":"Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"314","author":"Gross","year":"2015","journal-title":"JAMA"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Diabetic retinopathy clinical research network. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/S0140-6736(17)31193-5","article-title":"Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial","volume":"389","author":"Sivaprasad","year":"2017","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1001\/archopht.1985.01050110038020","article-title":"Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy: two-year results of a randomized trial. DRVS report 2","volume":"103","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/jamaophthalmol.2013.2015","article-title":"Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy","volume":"131","author":"Bhavsar","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1001\/jama.2020.23027","article-title":"DRCR Retina network. Effect of intravitreous aflibercept vs vitrectomy with panretinal photocoagulation on visual acuity in patients with vitreous hemorrhage from proliferative diabetic retinopathy: a randomized clinical trial","volume":"324","author":"Antoszyk","year":"2020","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"9","DOI":"10.36502\/2024\/droa.6187","article-title":"Developing research for five subtypes of diabetes with specific characteristics","volume":"5","author":"Bando","year":"2024","journal-title":"Asploro J Biomed Clin Case Rep"},{"key":"B31","doi-asserted-by":"publisher","first-page":"S261","DOI":"10.2337\/dc26-S012","article-title":"12. Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142026","volume":"49","author":"Bajaj","year":"2026","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"P66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e012","DOI":"10.48130\/vns-0025-0012","article-title":"Association between early inflammation and neurodegeneration in diabetic retinopathy: a narrative review","volume":"42","author":"Liu","year":"2025","journal-title":"Vis Neurosci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e005","DOI":"10.48130\/vns-0025-0005","article-title":"Effects of pars plana vitrectomy on retinal structure in severe non-proliferative diabetic retinopathy","volume":"42","author":"Liu","year":"2025","journal-title":"Vis Neurosci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1038\/s41591-026-04359-w","article-title":"AI Framework for multidisease detection via retinal imaging","volume":"32","author":"Zhang","year":"2026","journal-title":"Nat Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e003","DOI":"10.1017\/S0952523824000038","article-title":"Electroretinographic responses to periodic stimuli in primates and the relevance for visual perception and for clinical studies","volume":"41","author":"Bach","year":"2024","journal-title":"Vis Neurosci"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1904880\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:58:15Z","timestamp":1787907495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1904880\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":36,"alternative-id":["10.3389\/fmed.2026.1904880"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1904880","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"article-number":"1904880"}}